Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radium-223 chloride - Bayer HealthCare

Next Previous
X
Search
Drug Profile

Radium-223 chloride - Bayer HealthCare

Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Ra-223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo; XofigoR

Latest Information Update: 05 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Algeta
  • Developer Algeta; Bayer HealthCare; Janssen; Medica Scientia Innovation Research; Royal Marsden NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; The Institute of Cancer Research; Thomas Jefferson University; University of Texas M. D. Anderson Cancer Center
  • Class Analgesics; Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone metastases
  • Phase III Prostate cancer
  • Phase I/II Breast cancer; Non-small cell lung cancer
  • No development reported Osteosarcoma; Renal cell carcinoma
  • Discontinued Cancer pain; Multiple myeloma

Most Recent Events

  • 08 Feb 2024 Bayer compltes a phase III trial in Bone metastases (from castration-resistant, chemotherapy-naive prostate cancer; first-line therapy, combination therapy) in US, Canada, the UK, Finland, Germany, Israel, Singapore, Spain, Norway, Italy, Sweden, Belgium, the Netherlands, Poland, Australia, Brazil, France and Japan (IV) (NCT02043678)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Bone metastases(In the elderly, Second-line therapy or greater, In adults) in Austria (IV, Injection)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Bone metastases(In the elderly, Second-line therapy or greater, In adults) in Finland (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top